LSA
IOVA icon

Leonteq Securities AG’s Iovance Biotherapeutics IOVA Stock Holding History

Leonteq Securities AG’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$332K – 1297
2025
Q1 		$332K Buy
+100,000
New +$516K 0.02% 445

Other funds holding IOVA

MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
SMAM
Sugar Maple Asset Management Sister Bay, Wisconsin $155M AUM 17.72% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return

Leonteq Securities AG's IOVA Position: Q2 2026 in Review

Leonteq Securities AG reduced its Iovance Biotherapeutics (IOVA) stake by 6.3% in Q2 2026, selling an estimated $38K and leaving 150,000 shares worth $624K. The position accounts for 0.02% of the portfolio, ranked #357.

Leonteq Securities AG first reported a position in IOVA in Q4 2020 and has held it in 22 quarters since. 59 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Leonteq Securities AG held 150,000 shares of Iovance Biotherapeutics worth $624K as of Q2 2026.
  • Leonteq Securities AG sold 10,000 Iovance Biotherapeutics shares in Q2 2026, an estimated $38K.
  • Iovance Biotherapeutics made up 0.02% of Leonteq Securities AG's portfolio in Q2 2026, its #357 holding.
  • Leonteq Securities AG first reported a position in Iovance Biotherapeutics in Q4 2020 and has held it in 22 quarters since.
  • 59 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.